{"id":"W2761721053","doi":"10.1016/j.jcjo.2017.07.028","title":"Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors","year":2017,"lang":"en","type":"editorial","venue":"Canadian Journal of Ophthalmology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Novo Nordisk; Merck; Diabetes Canada; AstraZeneca","keywords":"Empagliflozin; Liraglutide; Medicine; Semaglutide; Type 2 diabetes; Metformin; Diabetes mellitus; Canagliflozin; Dulaglutide; Internal medicine; Glycemic; Pharmacology; Endocrinology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00564679,0.003332444,0.004520279,0.00301217,0.002403439,0.005817301,0.003338319,0.01836317,0.007796126],"category_scores_gemma":[0.01846674,0.001312178,0.003764927,0.001509505,0.001905331,0.004652614,0.001206427,0.02651698,0.006059463],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003733545,"about_ca_system_score_gemma":0.004228211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003060973,"about_ca_topic_score_gemma":0.01108812,"domain_scores_codex":[0.9954395,0.0006061203,0.0008520214,0.0003791818,0.002377084,0.0003461207],"domain_scores_gemma":[0.9813935,0.007227223,0.001702244,0.0003584898,0.006876474,0.002442065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000663906,0.00002280106,0.0000358647,0.0003579838,0.00002847701,0.0002384101,0.000008636825,0.00003036627,0.00006556064,0.0002168121,0.9868352,0.01209358],"study_design_scores_gemma":[0.0002280075,0.00007436277,0.0004042725,0.0009857411,0.00014568,0.0009202899,0.00005017673,0.0001861243,0.0001145838,0.0006426806,0.996214,0.00003406216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00004854028,0.01836977,0.0001179942,0.03840149,0.9418938,0.000015373,0.00003601546,0.00004010981,0.001076844],"genre_scores_gemma":[0.0002654189,0.01299135,0.0001294693,0.02658432,0.9564911,0.00001298178,0.00002462972,0.00001450858,0.003486285],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.01836317,"threshold_uncertainty_score":0.02986348,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02794586873220412,"score_gpt":0.301599796803221,"score_spread":0.2736539280710168,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}